Farxiga Tablet, Film Coated
NDC Package 70518-4614-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Farxiga (dapagliflozin) tablets is dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. This formulation utilizes a tablet, film coated delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-4614 and is authorized under FDA application NDA202293.

Identification & Billing

NDC Package Code
70518-4614-0
Package Description
50 POUCH in 1 BOX / 1 TABLET, FILM COATED in 1 POUCH (70518-4614-1)
Product Code
70518-4614
11-Digit Billing Format
70518461400
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Farxiga
Non-Proprietary Name
Dapagliflozin
Substance Name
Dapagliflozin Propanediol
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DAPAGLIFLOZIN PROPANEDIOL 5 mg/1
Pharmacologic Class
Usage Information
Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. This medication is also used in people with type 2 diabetes and heart disease to lower the risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sugar by your kidneys. Dapagliflozin is also used to treat heart failure. It may help you live longer and lower your risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sodium by your kidneys.

Regulatory & Marketing

Labeler Name
Remedyrepack Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA202293
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-23-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70518-4614-0 identifies a specific commercial package of 50 pouch in 1 box / 1 tablet, film coated in 1 pouch (70518-4614-1) of Farxiga, a human prescription drug labeled by Remedyrepack Inc.. This tablet, film coated is formulated for oral use and contains dapagliflozin propanediol as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on April 23, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. This medication is also used in people with type 2 diabetes and heart disease to lower the risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sugar by your kidneys. Dapagliflozin is also used to treat heart failure. It may help you live longer and lower your risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sodium by your kidneys.

How is this Remedyrepack Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518461400. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70518-4614-0
11-Digit CMS (5-4-2)
70518-4614-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.